Fmr LLC Caribou Biosciences, Inc. Transaction History

Fmr LLC

$1.52 Trillion
Q2 2024

A detailed history of Fmr LLC transactions in Caribou Biosciences, Inc. stock. As of the latest transaction made, Fmr LLC holds 1,471,887 shares of CRBU stock, worth $3.25 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,471,887

Previous 1,445,162 1.85%

Holding current value

$3.25 Million

Previous $7.43 Million 67.51%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$1.62 - $5.05 $43,294 - $134,961	26,725 Added 1.85%	1,471,887 $2.41 Million
Q1 2024 May 13, 2024	BUY	$4.82 - $8.26 $2,824 - $4,840	586 Added 0.04%	1,445,162 $7.43 Million
Q4 2023 Feb 13, 2024	SELL	$3.58 - $6.25 $2,216 - $3,868	-619 Reduced 0.04%	1,444,576 $8.28 Million
Q3 2023 Nov 13, 2023	BUY	$4.08 - $8.14 $8,188 - $16,336	2,007 Added 0.14%	1,445,195 $6.91 Million
Q2 2023 Aug 11, 2023	SELL	$4.04 - $5.47 $2,565 - $3,473	-635 Reduced 0.04%	1,443,188 $6.13 Million
Q1 2023 May 11, 2023	BUY	$4.3 - $7.78 $3,341 - $6,045	777 Added 0.05%	1,443,823 $7.67 Million
Q4 2022 Feb 13, 2023	SELL	$5.57 - $11.01 $3,046 - $6,022	-547 Reduced 0.04%	1,443,046 $9.06 Million
Q3 2022 Nov 10, 2022	SELL	$5.34 - $12.79 $431,162 - $1.03 Million	-80,742 Reduced 5.3%	1,443,593 $15.2 Million
Q2 2022 Aug 12, 2022	SELL	$5.1 - $9.74 $2.49 Million - $4.76 Million	-488,698 Reduced 24.28%	1,524,335 $8.28 Million
Q1 2022 May 13, 2022	SELL	$8.42 - $15.32 $11 Million - $20.1 Million	-1,310,251 Reduced 39.43%	2,013,033 $18.5 Million
Q3 2021 Nov 15, 2021	BUY	$15.75 - $30.29 $52.3 Million - $101 Million	3,323,284 New	3,323,284 $79.3 Million

Others Institutions Holding CRBU

# of Institutions

141

Shares Held

53.3M

Call Options Held

32.5K

Put Options Held

89.8K

View Full List

About Caribou Biosciences, Inc.

Ticker CRBU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,840,800
Market Cap $134M
Description
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1...

More about CRBU

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fmr LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fmr LLC with notifications on news.

Account